Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week Low - Time to Sell?

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The stock traded as low as $5.61 and last traded at $5.59, with a volume of 181454 shares. The stock had previously closed at $5.64.

Analyst Upgrades and Downgrades

FOLD has been the topic of several analyst reports. The Goldman Sachs Group dropped their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating on the stock in a research report on Friday, May 2nd. Wall Street Zen cut Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, May 5th. Finally, UBS Group increased their price objective on Amicus Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Four equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Price Performance

The company has a debt-to-equity ratio of 2.02, a current ratio of 3.34 and a quick ratio of 2.47. The stock's 50 day moving average price is $6.39 and its two-hundred day moving average price is $8.16. The firm has a market capitalization of $1.76 billion, a price-to-earnings ratio of -63.44 and a beta of 0.54.

Institutional Trading of Amicus Therapeutics

A number of hedge funds have recently bought and sold shares of the stock. Summit Investment Advisors Inc. increased its stake in Amicus Therapeutics by 4.4% during the fourth quarter. Summit Investment Advisors Inc. now owns 30,696 shares of the biopharmaceutical company's stock valued at $289,000 after acquiring an additional 1,280 shares during the period. Diversified Trust Co increased its position in shares of Amicus Therapeutics by 2.2% during the first quarter. Diversified Trust Co now owns 83,542 shares of the biopharmaceutical company's stock valued at $682,000 after purchasing an additional 1,784 shares during the period. Tempus Wealth Planning LLC raised its stake in shares of Amicus Therapeutics by 7.2% in the first quarter. Tempus Wealth Planning LLC now owns 29,513 shares of the biopharmaceutical company's stock valued at $241,000 after purchasing an additional 1,990 shares in the last quarter. Xponance Inc. lifted its position in Amicus Therapeutics by 11.9% in the fourth quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company's stock worth $200,000 after purchasing an additional 2,249 shares during the period. Finally, Covestor Ltd lifted its position in Amicus Therapeutics by 114.9% in the fourth quarter. Covestor Ltd now owns 4,325 shares of the biopharmaceutical company's stock worth $41,000 after purchasing an additional 2,312 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.